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Over the last thirty years, research on tryptophan has progressively moved from an almost “obscure” to a primary 
field of research. Over the last decade, interest in tryptophan and thus number of publications on the subject has 
been significantly growing. Looking at Pubmed today (March 2010), the overall number of publications about 
tryptophan, indoleamine 2,3 dioxygenase (IDO), and the kynurenine pathway has been rising significantly (Fig. 1). 
Tryptophan research got its first “boost” in the eighties with the identification of neuroactive compounds such as 
quinolinic acid and kynurenic acid and their actions as agonist and antagonist of the N-methyl-D-aspartate recep-
tor. Then, the field was subject to another major discovery when IDO-1 was identified as a key regulator of the 
immune response. Publications on IDO have the highest growth rate as shown on Figure 1. More Recently, a study 
has demonstrated that kynurenic acid is implicated in the regulation of the leukocytes binding on the endothelium 
(Barth et al 2009, The Journal of biological Chemistry) and a second one showed that kynurenine is a potent 
vasodilator (Wang et al 2010, Nature Medicine) highlighting the essential roles played by some of the tryptophan 
metabolites in both physiological and pathological conditions. This is likely to be only the tip of the iceberg.
For the past 35 years the Executive Committee of the International Society for Tryptophan Research (ISTRY) 
has been organizing triennial meetings in order to cover most of the incumbent key scientific information on 
chemical and biological aspects of Tryptophan research. The first of those meetings was held in Padua in 1974. 
Since then a significant number of scientists with completely different backgrounds (chemists, anatomists, molec-
ular biologists, immunologists, embryologists, neuroscientists, psychiatrists, oncologists, etc.) have been present-
ing and discussing their data on the roles of tryptophan and its main metabolites in animal and human nutrition, 
behaviour and other aspects of physiology and pathology.Guillemin
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Past meetings have been alternatively organized in 
Japan, USA and Europe. Prof. Flavio Moroni chaired 
the 2009 edition of the meeting in Florence, Italy. 
It was a really successful meeting with high quality 
speakers and presentations.
During this 12th ISTRY Meeting most of the aspects 
of tryptophan research have been broached including 
the neuroscience, metabolism, psychology, inflamma-
tion, nutrition, molecular, cellular, enzyme, immune 
regulation, medicinal chemistry, and analytical chem-
istry domains. Several of the key speakers have kindly 
agreed to write a short manuscript related to their pre-
sentations in a special issue of the International jour-
nal for Tryptophan Research (IJTR). These include 
reviews and original scientific reports describing the 
involvement of the tryptophan catabolites in several 
diseases, new mechanisms involved in immune regu-
lation and new enzyme variants.
The next ISTRY meeting will take place in   Sydney, 
Australia in 2012 and will be hosted by Dr. Gilles 
Guillemin. We hope that many more scientists working 
on tryptophan research will join ISTRY over the next 
3 years and attend this 13th ISTRY meeting.
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Figure 1. Evolution of the publications in the field of tryptophan research 
over the last 10 year.